KPRX — Kiora Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $13.37m
- -$17.91m
- 61
- 99
- 69
- 90
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.32 | ||
| Price to Tang. Book | 0.42 | ||
| Price to Free Cashflow | 1.55 | ||
| Price to Sales | 0.69 | ||
| EV to EBITDA | -7.78 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.25% | ||
| Return on Equity | 10.11% | ||
| Operating Margin | 15.95% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.69 | 0.01 | n/a | n/a | n/a | 16.5 | 3 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).
Directors
- Paul Chaney CHM (63)
- Brian Strem PRE (42)
- Sarah Romano CFO (41)
- Franz Obermayr EVP (52)
- Eric Daniels OTH (49)
- Kenneth Gayron IND (51)
- David Hollander IND (47)
- Erin Parsons IND (46)
- Aron Shapiro IND (43)
- Praveen Tyle IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- December 28th, 2004
- Public Since
- February 13th, 2015
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,970,568
- Address
- 332 ENCINITAS BOULEVARD, SUITE 102, ENCINITAS, 92024
- Web
- https://kiorapharma.com/
- Phone
- +1 7817888869
- Auditors
- EisnerAmper LLP
Upcoming Events for KPRX
Q3 2024 Kiora Pharmaceuticals Inc Earnings Release
Similar to KPRX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Kiora Pharmaceuticals share price?
As of Today at 21:38 UTC, shares in Kiora Pharmaceuticals are trading at $3.72. This share price information is delayed by 15 minutes.
How has the Kiora Pharmaceuticals share price performed this year?
Shares in Kiora Pharmaceuticals last closed at $3.72 and the price had moved by -42.58% over the past 365 days. In terms of relative price strength the Kiora Pharmaceuticals share price has underperformed the S&P500 Index by -54.31% over the past year.
What are the analyst and broker recommendations for Kiora Pharmaceuticals?
The overall consensus recommendation for Kiora Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Kiora Pharmaceuticals dividend yield?
Kiora Pharmaceuticals does not currently pay a dividend.
Does Kiora Pharmaceuticals pay a dividend?
Kiora Pharmaceuticals does not currently pay a dividend.
When does Kiora Pharmaceuticals next pay dividends?
Kiora Pharmaceuticals does not currently pay a dividend.
How do I buy Kiora Pharmaceuticals shares?
To buy shares in Kiora Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kiora Pharmaceuticals?
As of the previous close price of $3.72, shares in Kiora Pharmaceuticals had a market capitalisation of $11.05m.
Where are Kiora Pharmaceuticals shares listed?
Here are the trading details for Kiora Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: KPRX
What kind of share is Kiora Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Kiora Pharmaceuticals is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kiora Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Kiora Pharmaceuticals is $33.00. That is 787.1% above the last closing price of $3.72.
Analysts covering Kiora Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $0.93 for the next financial year.
What is the trend in the Kiora Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kiora Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -33%.
As of the last closing price of $3.72, shares in Kiora Pharmaceuticals were trading -27.64% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kiora Pharmaceuticals PE Ratio?
The Kiora Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kiora Pharmaceuticals?
Kiora Pharmaceuticals' management team is headed by:
- Paul Chaney - CHM
- Brian Strem - PRE
- Sarah Romano - CFO
- Franz Obermayr - EVP
- Eric Daniels - OTH
- Kenneth Gayron - IND
- David Hollander - IND
- Erin Parsons - IND
- Aron Shapiro - IND
- Praveen Tyle - IND